Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - EQ 10GM BASE/...DOSAGE - INJECTABLE;INJECTION - EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50547
DOSAGE - INJECTABLE;INJECTION - EQ 1GM BASE/V...DOSAGE - INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50547
DOSAGE - INJECTABLE;INJECTION - EQ 2GM BASE/V...DOSAGE - INJECTABLE;INJECTION - EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50547
DOSAGE - INJECTABLE;INJECTION - EQ 500MG BASE...DOSAGE - INJECTABLE;INJECTION - EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50547
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
70
PharmaCompass offers a list of Cefotaxime API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cefotaxime manufacturer or Cefotaxime supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cefotaxime manufacturer or Cefotaxime supplier.
PharmaCompass also assists you with knowing the Cefotaxime API Price utilized in the formulation of products. Cefotaxime API Price is not always fixed or binding as the Cefotaxime Price is obtained through a variety of data sources. The Cefotaxime Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cefotaxime manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cefotaxime, including repackagers and relabelers. The FDA regulates Cefotaxime manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cefotaxime API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cefotaxime manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cefotaxime supplier is an individual or a company that provides Cefotaxime active pharmaceutical ingredient (API) or Cefotaxime finished formulations upon request. The Cefotaxime suppliers may include Cefotaxime API manufacturers, exporters, distributors and traders.
click here to find a list of Cefotaxime suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cefotaxime DMF (Drug Master File) is a document detailing the whole manufacturing process of Cefotaxime active pharmaceutical ingredient (API) in detail. Different forms of Cefotaxime DMFs exist exist since differing nations have different regulations, such as Cefotaxime USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cefotaxime DMF submitted to regulatory agencies in the US is known as a USDMF. Cefotaxime USDMF includes data on Cefotaxime's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cefotaxime USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cefotaxime suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cefotaxime Drug Master File in Japan (Cefotaxime JDMF) empowers Cefotaxime API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cefotaxime JDMF during the approval evaluation for pharmaceutical products. At the time of Cefotaxime JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cefotaxime suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cefotaxime Drug Master File in Korea (Cefotaxime KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cefotaxime. The MFDS reviews the Cefotaxime KDMF as part of the drug registration process and uses the information provided in the Cefotaxime KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cefotaxime KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cefotaxime API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cefotaxime suppliers with KDMF on PharmaCompass.
A Cefotaxime CEP of the European Pharmacopoeia monograph is often referred to as a Cefotaxime Certificate of Suitability (COS). The purpose of a Cefotaxime CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Cefotaxime EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Cefotaxime to their clients by showing that a Cefotaxime CEP has been issued for it. The manufacturer submits a Cefotaxime CEP (COS) as part of the market authorization procedure, and it takes on the role of a Cefotaxime CEP holder for the record. Additionally, the data presented in the Cefotaxime CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Cefotaxime DMF.
A Cefotaxime CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Cefotaxime CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Cefotaxime suppliers with CEP (COS) on PharmaCompass.
A Cefotaxime written confirmation (Cefotaxime WC) is an official document issued by a regulatory agency to a Cefotaxime manufacturer, verifying that the manufacturing facility of a Cefotaxime active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cefotaxime APIs or Cefotaxime finished pharmaceutical products to another nation, regulatory agencies frequently require a Cefotaxime WC (written confirmation) as part of the regulatory process.
click here to find a list of Cefotaxime suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cefotaxime as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cefotaxime API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cefotaxime as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cefotaxime and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cefotaxime NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cefotaxime suppliers with NDC on PharmaCompass.
Cefotaxime Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cefotaxime GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cefotaxime GMP manufacturer or Cefotaxime GMP API supplier for your needs.
A Cefotaxime CoA (Certificate of Analysis) is a formal document that attests to Cefotaxime's compliance with Cefotaxime specifications and serves as a tool for batch-level quality control.
Cefotaxime CoA mostly includes findings from lab analyses of a specific batch. For each Cefotaxime CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cefotaxime may be tested according to a variety of international standards, such as European Pharmacopoeia (Cefotaxime EP), Cefotaxime JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cefotaxime USP).
